Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2017

Open Access 01-12-2017 | Research

Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung’s disease in newborns – a nationwide cohort study

Authors: Sebastian Werngreen Nielsen, Perniller Møller Ljungdalh, Jan Nielsen, Bente Mertz Nørgård, Niels Qvist

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Login to get access

Abstract

Background

Hirschsprung’s disease is a rare condition caused by congenital malformation of the gastrointestinal tract affecting 1:5000 children. Not much is known about risk factors for development of Hirschsprung’s disease. Two clinical cases of hirschsprung’s disease led to an investigation of the association between maternal use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and development of Hirschsprung’s Disease in the newborn child. The study examined a nationwide, unselected cohort of children born in Denmark from 1 January 1996 until 12 March 2016 (n = 1,256,317). We applied multivariate models to register-based data to estimate the odds ratio of Hirschsprung’s disease, adjusting for possible confounders. The studied exposure period for SSRIs were 30 days prior to conception to the end of the first trimester.

Results

In the main exposed cohort the prevalence of Hirschsprung’s disease was 16/19.807 (0.08%) compared to 584/1.236.510 (0.05%) in the unexposed cohort. In women who redeemed a minimum of one prescription of selective serotonin reuptake inhibitors, the adjusted odds ratio for development of Hirschsprung’s disease was 1.76 (95%CI: 1.07–2.92). In women who redeemed a minimum of two prescriptions, the adjusted odds ratio for Hirschsprung’s disease was 2.34 (95% CI: 1.21–4.55).

Conclusions

Our data suggest that early maternal use of selective serotonin reuptake inhibitors is significantly associated with the development of Hirschsprung’s disease in the newborn child. Treatment of depression during pregnancy always has to be weighed against the risks posed by untreated maternal depression. Our results have to be confirmed in other studies.
Appendix
Available only for authorised users
Literature
1.
Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198:194. e1-5CrossRefPubMed
2.
Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One. 2013;8:e63034.CrossRefPubMedPubMedCentral
3.
Bakker MK, Kölling P, van den Berg PB, de Walle HEK, de Jong van den Berg LTW. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65:600–6.CrossRefPubMed
4.
Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birt Defects Res A Clin Mol Teratol. 2011;91:142–52.CrossRef
5.
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898–906.CrossRefPubMed
6.
Knudsen TM, Hansen AV, Garne E, Andersen A-MN. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy – an epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth. 2014;14 doi:10.​1186/​1471-2393-14-333.
7.
Wemakor A, Casson K, Garne E, Bakker M, Addor M-C, Arriola L, et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol. 2015;30:1187–98.CrossRefPubMed
8.
Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118:111–20.CrossRefPubMed
9.
Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. BMJ.  2015;8;351:h3190.
10.
Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012;2:e001148.CrossRefPubMedPubMedCentral
11.
Malm H. Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome. Ther Drug Monit. 2012;34:607–14.CrossRefPubMed
12.
Tuccori M, Montagnani S, Testi A, Ruggiero E, Mantarro S, Scollo C, et al. Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update. Postgrad Med. 2010;122:49–65.CrossRefPubMed
13.
Margulis AV, Abou-Ali A, Strazzeri MM, Ding Y, Kuyateh F, Frimpong EY, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD: SSRIS AND CARDIAC MALFORMATIONS. Pharmacoepidemiol Drug Saf. 2013;:n/a-n/a.
14.
Källén BAJ, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birt Defects Res A Clin Mol Teratol. 2007;79:301–8.CrossRef
15.
Nordeng H, van Gelder MMHJ, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. J Clin Psychopharmacol. 2012;32:186–94.CrossRefPubMed
16.
Hansson SR, Mezey E, Hoffman BJ. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience. 1999;89:243–65.CrossRefPubMed
17.
Li Z, Chalazonitis A, Huang Y-Y, Mann JJ, Margolis KG, Yang QM, et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric Dopaminergic neurons. J Neurosci. 2011;31:8998–9009.CrossRefPubMedPubMedCentral
18.
19.
Butler Tjaden NE, Trainor PA. The developmental etiology and pathogenesis of Hirschsprung disease. Transl Res. 2013;162:1–15.CrossRefPubMed
20.
Rintala RJ, Pakarinen MP. Long-term outcomes of Hirschsprung’s disease. Semin Pediatr Surg. 2012;21:336–43.CrossRefPubMed
21.
Best KE, Glinianaia SV, Bythell M, Rankin J. Hirschsprung’s disease in the north of England: prevalence, associated anomalies, and survival. Birt Defects Res A Clin Mol Teratol. 2012;94:477–80.CrossRef
22.
Best KE, Addor M-C, Arriola L, Balku E, Barisic I, Bianchi F, et al. Hirschsprung’s disease prevalence in Europe: a register based study: Hirschsprung’s disease in Europe. Birt Defects Res A Clin Mol Teratol. 2014;100:695–702.CrossRef
23.
Bergeron K-F, Silversides D, Pilon N. The developmental genetics of Hirschsprung’s disease: developmental genetics of Hirschsprung’s disease. Clin Genet. 2013;83:15–22.CrossRefPubMed
24.
Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl):30–3.CrossRefPubMed
25.
Knudsen LB, Olsen J. The Danish medical birth Registry. Dan Med Bull. 1998;45:320–3.PubMed
26.
Wallach Kildemoes H, Toft Sorensen H, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38–41.CrossRef
27.
Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006;53:441–9.PubMed
28.
World Health Organization. International statistical classification of diseases and health related problems (the) ICD-10. 2004.
29.
World Health Organization. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs). 2004.
30.
Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: the Danish National Database of reimbursed prescriptions. Clin Epidemiol. 2012;4:303–13.CrossRefPubMedPubMedCentral
31.
De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP group. Europen medicine and pregnancy group. Teratology. 1999;60:33–6.CrossRefPubMed
32.
Sarangarm P, Young B, Rayburn W, Jaiswal P, Dodd M, Phelan S, et al. Agreement between self-report and prescription data in medical records for pregnant women. Birt Defects Res A Clin Mol Teratol. 2012;94:153–61.CrossRef
33.
Pisa FE, Casetta A, Clagnan E, Michelesio E, Vecchi Brumatti L, Barbone F. Medication use during pregnancy, gestational age and date of delivery: agreement between maternal self-reports and health database information in a cohort. BMC Pregnancy Childbirth. 2015;15:310.CrossRefPubMedPubMedCentral
34.
Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, et al. Do pregnant women report use of dispensed medications? Epidemiol Camb Mass. 2001;12:497–501.CrossRef
35.
Källén B, Nilsson E, Olausson PO. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol. 2011;67:839–45.CrossRefPubMed
36.
Waters CS, Hay DF, Simmonds JR, van Goozen SHM. Antenatal depression and children’s developmental outcomes: potential mechanisms and treatment options. Eur Child Adolesc Psychiatry. 2014;23:957–71.CrossRefPubMed
37.
Olivier JDA, Åkerud H, Kaihola H, Pawluski JL, Skalkidou A, Högberg U, et al. The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. Front Cell Neurosci. 2013;7 doi:10.​3389/​fncel.​2013.​00073.
38.
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009;31:403–13.CrossRefPubMedPubMedCentral
39.
Smoller JW. The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology. 2016;41:297–319.CrossRefPubMed
40.
Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, et al. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet. 2007;45:1–14.CrossRefPubMed
41.
Torroglosa A, Alves MM, Fernández RM, Antiñolo G, Hofstra RM, Borrego S. Epigenetics in ENS development and Hirschsprung disease. Dev Biol. 2016;15(417(2)):209–16.CrossRef
42.
Devlin AM, Brain U, Austin J, Oberlander TF. Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS One. 2010;5:e12201.CrossRefPubMedPubMedCentral
43.
Schroeder JW, Smith AK, Brennan PA, Conneely KN, Kilaru V, Knight BT, et al. DNA methylation in neonates born to women receiving psychiatric care. Epigenetics. 2012;7:409–14.CrossRefPubMedPubMedCentral
44.
Sergi C, Caluseriu O, McColl H, Eisenstat DD. Hirschsprung’s disease: clinical Dysmorphology, genes. Micro-RNAs Future Perspectives Pediatr Res. 2016; doi:10.​1038/​pr.​2016.​202.
45.
46.
Heuckeroth RO, Schäfer K-H. Gene-environment interactions and the enteric nervous system: neural plasticity and Hirschsprung disease prevention. Dev Biol. 2016;15(417(2)):188–97.CrossRef
47.
Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. 2011;17:589–604.CrossRefPubMedPubMedCentral
48.
Löf Granström A, Svenningsson A, Hagel E, Oddsberg J, Nordenskjöld A, Wester T. Maternal risk factors and Perinatal characteristics for Hirschsprung disease. Pediatrics. 2016;138(1).
49.
Fu M, Sato Y, Lyons-Warren A, Zhang B, Kane MA, Napoli JL, et al. Vitamin a facilitates enteric nervous system precursor migration by reducing Pten accumulation. Dev Camb Engl. 2010;137:631–40.
50.
Knudsen VK, Orozova-Bekkevold I, Rasmussen LB, Mikkelsen TB, Michaelsen KF, Olsen SF. Low compliance with recommendations on folic acid use in relation to pregnancy: is there a need for fortification? Public Health Nutr. 2004;7 doi:10.​1079/​PHN2004630.
Metadata
Title
Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung’s disease in newborns – a nationwide cohort study
Authors
Sebastian Werngreen Nielsen
Perniller Møller Ljungdalh
Jan Nielsen
Bente Mertz Nørgård
Niels Qvist
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-017-0667-4

Other articles of this Issue 1/2017

Orphanet Journal of Rare Diseases 1/2017 Go to the issue

Research

Fifteen-year follow-up of Italian families affected by arginine glycine amidinotransferase deficiency

Research

Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

Research

Central nervous system manganese induced lesions and clinical consequences in patients with hereditary hemorrhagic telangiectasia

Letter to the Editor

Mimicking hypersensitivity pneumonitis as an uncommon initial presentation of chronic granulomatous disease in children

Research

Clinical and genetic characteristics of chinese patients with Birt-Hogg-Dubé syndrome

Review

The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review